Alluvi, previously BI 4744, presents a promising breakthrough in obesity care. This dual stimulator targeting both GLP-1 and GIP targets demonstrates impressive effectiveness in clinical trials, potentially surpassing https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/